SCHEMBL6980256

SCHEMBL6980256

Cc1cccc([C@H](O)CO)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.44
ACP3 P15309 1/20 0.44
ACHE P22303 2/20 0.44
TAAR1 Q96RJ0 1/20 0.43
HIF1A Q16665 3/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRB3 P13945 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
NFKB1 P19838 1/20 0.42
DRD1 P21728 1/20 0.42
HTR7 P34969 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
DRD3 P35462 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16072433 1.00 TSHR (0.44) TSHRCYP3A4ACP3ACHETAAR1
SCHEMBL22785850 1.00 TSHR (0.44) TSHRCYP3A4ACP3ACHETAAR1
SCHEMBL31376562 1.00 TSHR (0.44) TSHRCYP3A4ACP3ACHETAAR1
SCHEMBL14038059 0.84 TSHR (0.47) TSHRCYP3A4HIF1AADRB2ADRB1
SCHEMBL3196398 0.84 ACP3 (0.42) TSHRACP3ACHETAAR1HIF1A
SCHEMBL3928172 0.83 LMNA (0.59) TSHRACP3ACHETAAR1HIF1A
SCHEMBL13657377 0.83 LMNA (0.59) TSHRACP3ACHETAAR1HIF1A
SCHEMBL875416 0.83 LMNA (0.59) TSHRACP3ACHETAAR1HIF1A
SCHEMBL7787303 0.83 ACP3 (0.44) TSHRACP3ACHETAAR1HIF1A
SCHEMBL24454254 0.82 PNMT (0.56) TSHRCYP3A4ACP3ACHETAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS DR. REDDY'S LABORATORIES, LTD. (IN) 2017-01-05 US disclosed
US-9487510-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists DR. REDDY'S LABORATORIES LTD. (IN) 2016-11-08 US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 US disclosed
EP-0817772-B1 PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS PFIZER (US) 2003-01-29 EP disclosed
US-6110947-A AN ANALGESIC AGENT FOR TREATING STROKE, ABDOMINAL PAIN; AS ANTIINFLAMMATORY, DIURETIC, ANESTHETIC OR NEUROPROTECTIVE AGENTS PFIZER INC. (US) 2000-08-29 US disclosed
US-5952369-A ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE PFIZER INC (US) 1999-09-14 US disclosed
EP-0817772-A1 PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS PFIZER INC. (US) 1998-01-14 EP disclosed
WO-1996030339-A1 PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS PFIZER INC. (US) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS OPRK1, OPRL1, OPRD1 TSHR 670/4885CYP3A4 716/4885ACP3 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.